{"id":10137,"date":"2026-04-23T02:13:21","date_gmt":"2026-04-23T07:13:21","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10137"},"modified":"2026-04-23T02:24:51","modified_gmt":"2026-04-23T07:24:51","slug":"nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","title":{"rendered":"Nanoscope Therapeutics anuncia su participaci\u00f3n en las reuniones anuales de Eyecelerator\u00ae y ARVO 2026."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10137\" class=\"elementor elementor-10137\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 style=\"text-align: center;\"><em>Presentaciones para destacar la eficacia, durabilidad y seguridad de primera clase de las plataformas de terapia optogen\u00e9tica de Nanoscope.<\/em><\/h3><p>\u00a0<\/p><p><strong>DALLAS, TX, 20 de abril<sup>th<\/sup>, 2026<\/strong> \u2013 <a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/nanostherapeutics.com\/___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm86ZjJlNmE2OTc0NDhjOTExNjcxOTU2OWFiZGNmNTE2OGU6Nzo3MGYwOjZjMDU0OGFiMTI3YjZmODc0OGQ5Y2I3NmU4ZGU4YWU4NTdiNWNlMTljNTlmMzc2N2UxMWE5NWZiMWIzYzE1MGE6cDpUOlQ\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy su participaci\u00f3n y presentaciones en la Asociaci\u00f3n para la Investigaci\u00f3n en Visi\u00f3n y Oftalmolog\u00eda. <a href=\"https:\/\/www.arvo.org\/annual-meeting\">Reuni\u00f3n Anual de ARVO 2026<\/a> y <a href=\"https:\/\/www.eyecelerator.com\/arvo-2026\">Eyecelerator @ ARVO 2026<\/a> en Denver, Colorado.<\/p><p>\u201cNos enorgullece tener una s\u00f3lida presencia en ARVO y Eyecelerator, y presentar evidencia adicional de un beneficio cl\u00ednico significativo en pacientes con retinosis pigmentaria tratados con nuestra terapia de opsina multicaracter\u00edstica (MCO)\u201d, declar\u00f3 el Dr. Samuel Barone, director m\u00e9dico de Nanoscope. \u201cLa mejora sostenida de la visi\u00f3n durante varios a\u00f1os con un solo tratamiento tiene el potencial de ser verdaderamente transformadora para los pacientes y subraya a\u00fan m\u00e1s el potencial de MCO-010. A medida que nos acercamos a completar nuestra solicitud de licencia biol\u00f3gica y a prepararnos para la comercializaci\u00f3n, creemos que el impulso de Nanoscope contin\u00faa creciendo\u201d.\u201d<\/p><p><strong>Los detalles de las presentaciones son los siguientes:<\/strong><\/p><p><strong>Eyecelerator @ ARVO 2026<br \/><\/strong>Viernes, 1 de mayo<sup>calle<\/sup>, 2026<br \/>Sal\u00f3n Bluebird, Centro de Convenciones de Colorado, Denver, CO<\/p><p><strong>Miembro del jurado:<\/strong> Dr. Samarendra Mohanty, Presidente y Director Cient\u00edfico<br \/><strong>T\u00edtulo:<\/strong> \u00bfSe vislumbra una mejora de la visi\u00f3n gracias a la medicina regenerativa?<br \/><strong>Sesi\u00f3n:<\/strong> S5<br \/><strong>Fecha y hora:<\/strong> Viernes, 1 de mayo | 11:45 a. m. \u2013 12:45 p. m. MDT<\/p><p>\u00a0<\/p><p><strong>ARVO, la Asociaci\u00f3n para la Investigaci\u00f3n en Visi\u00f3n y Oftalmolog\u00eda.<br \/><\/strong>Domingo, 3 de mayo<sup>tercero<\/sup> hasta el jueves 7 de mayo<sup>th<\/sup>, 2026<br \/>Centro de Convenciones de Colorado, Denver, CO<\/p><p><strong>Presentador:<\/strong> Dr. Saurav Mohanty<br \/><strong>T\u00edtulo:<\/strong> Biodistribuci\u00f3n y expresi\u00f3n retiniana de la opsina multicaracter\u00edstica MCO-020 en primates tras la administraci\u00f3n intrav\u00edtrea no viral mediada por nanobarras de oro activadas con l\u00e1ser de infrarrojo cercano.<br \/><strong>Sesi\u00f3n: <\/strong>106, AMD: Nuevos f\u00e1rmacos, sistemas de administraci\u00f3n y mecanismos de acci\u00f3n I<br \/><strong>Fecha y hora:<\/strong> Domingo, 3 de mayo | 8:00 a. m. \u2013 9:45 a. m. MDT<\/p><p><strong>Presentador:<\/strong> El Dr. Vinit Mahajan, profesor de Oftalmolog\u00eda y vicedirector de Investigaci\u00f3n de la Universidad de Stanford,<br \/><strong>T\u00edtulo:<\/strong> Datos del estudio optogen\u00e9tico REMAIN de 3 a\u00f1os: mejora visual duradera con MCO-010 en el ensayo RESTORE de fase 2b\/3 para la retinosis pigmentaria.<br \/><strong>Sesi\u00f3n: <\/strong>306, Enfermedad retiniana hereditaria<br \/><strong>Fecha y hora:<\/strong> Martes, 5 de mayo | 8:30 a. m. \u2013 8:45 a. m. MDT<\/p><p><strong>Presentador:<\/strong> Dr. Samarendra Mohanty<br \/><strong>T\u00edtulo:<\/strong> Transferencia contralateral de AAV MCO-010 y transducci\u00f3n retiniana tras administraci\u00f3n intrav\u00edtrea unilateral<br \/><strong>Sesi\u00f3n: <\/strong>453, Terapias y edici\u00f3n gen\u00e9tica<br \/><strong>Fecha y hora:<\/strong> Mi\u00e9rcoles, 6 de mayo | 14:00 - 15:45 MDT<\/p><p>\u201cLos resultados a tres a\u00f1os del ensayo RESTORE demuestran que MCO-010 puede proporcionar un beneficio funcional duradero para los pacientes con retinosis pigmentaria y respaldan a\u00fan m\u00e1s la promesa de los enfoques optogen\u00e9ticos para la restauraci\u00f3n de la visi\u00f3n\u201d, dijo el Dr. Allen Ho., <a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/nanostherapeutics.com\/Bmt-Bj-fwjdfqqjs-mt-Afhd___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm86MGQ2M2Y3MTE4ZDQ1MDdjOTRiMmE1ZTM3M2Y4YzRhMjU6NzpjNDBkOjgxNzQyNjA4NTM5NDhlZTlhZWUyNjFmZDBmMjJjOWRjYWIyZTNmMTBmNjI0Mjg3MWMxMjdhODFmMGI3ZWYyZjM6cDpUOlQ\">Director de Investigaci\u00f3n de Retina en el Wills Eye Hospital y Asesor M\u00e9dico Jefe de Nanoscope.<\/a>. \u201cLos datos adicionales sobre las plataformas MCO-010 (AAV) y MCO-020 (no virales) en primates no humanos ampl\u00edan nuestra comprensi\u00f3n de la din\u00e1mica de administraci\u00f3n y respaldan el avance continuo de estos programas.\u201d<\/p><p>Los miembros del equipo de Nanoscope estar\u00e1n disponibles en el stand 6065 durante toda la duraci\u00f3n de la conferencia ARVO.<\/p><p><strong>Acerca de la plataforma MCO<br \/><\/strong>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><strong>Acerca de Nanoscope Therapeutics<br \/><\/strong>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (<a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/clinicaltrials.gov\/xyziDdSHY59c9\/aa7___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm86ZjJlNmE2OTc0NDhjOTExNjcxOTU2OWFiZGNmNTE2OGU6NzpiMGI4OjViYTdiODc0OGQ5ZWQ5YzYwZjllMDRlYWUzMmQzOTE4NDVhMjViZGQzMmRiMmZlMmE5NGZjODViZDE4MGM2NDI6cDpUOlQ\">NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/clinicaltrials.gov\/xyziDdSHY5\/96a67*~*___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm86ZjJlNmE2OTc0NDhjOTExNjcxOTU2OWFiZGNmNTE2OGU6NzoyMjBlOjRkMDAyYjMxZDYxZTMwNmU1NzYxYTM5NjE1MTI5MjA2YWZhNWVmOWE1ZmM3NGY5YzNmOTZlZjFhYThhNzRmMDY6cDpUOlQ\">NCT05417126<\/a>) y planea iniciar una <a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/nanostherapeutics.com\/7579d5cd67dsfstxhtuj-ymjwfujzynhx-fsstzshjx-jsi-tk-umfxj-7-rjjynsl-Bnym-z-x-kif-fsi-uqfs-yt-nsnynfyj-f-umfxj-8-hqnsnhfq-ywnfq-tk-rht-565-yt-ywjfy-xyfwlfwiy-rfhzqfw-ijljsjwfyntsd___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm86ZjJlNmE2OTc0NDhjOTExNjcxOTU2OWFiZGNmNTE2OGU6Nzo5ODMxOjlmZGY4YjVlNzJiZWM0ZWNkY2FlNTM3ZjFjMWFkZDlmNGFlYzc1Y2U4NjAwZTZkOWUyOWQ3ZjZkYTc1NWQ2NzI6cDpUOlQ\">Ensayo de registro de fase 3<\/a> En 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, as\u00ed como las designaciones Sakigake y hu\u00e9rfana de la PMDA para distrofias retinianas hereditarias (IRD) y las designaciones hu\u00e9rfana de la EMA y la SFDA para IRD. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p><p><strong>Contacto:<br \/><\/strong>Nanoscope Therapeutics, Inc.<br \/>+1 (817) 857-1186<br \/>PR@nanostherapeutics.com<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Presentations to highlight Nanoscope\u2019s best-in-class efficacy, durability, and safety of optogenetic therapy platforms \u00a0 DALLAS, TX, April 20th, 2026 \u2013 Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced participation and presentations at the Association for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10138,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10137","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T07:13:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T07:24:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings\",\"datePublished\":\"2026-04-23T07:13:21+00:00\",\"dateModified\":\"2026-04-23T07:24:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\"},\"wordCount\":697,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\",\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"datePublished\":\"2026-04-23T07:13:21+00:00\",\"dateModified\":\"2026-04-23T07:24:51+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"width\":960,\"height\":960},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia su participaci\u00f3n en las reuniones anuales de Eyecelerator\u00ae y ARVO 2026 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-04-23T07:13:21+00:00","article_modified_time":"2026-04-23T07:24:51+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings","datePublished":"2026-04-23T07:13:21+00:00","dateModified":"2026-04-23T07:24:51+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/"},"wordCount":697,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","url":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","name":"Nanoscope Therapeutics anuncia su participaci\u00f3n en las reuniones anuales de Eyecelerator\u00ae y ARVO 2026 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","datePublished":"2026-04-23T07:13:21+00:00","dateModified":"2026-04-23T07:24:51+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","width":960,"height":960},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10137"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10137\/revisions"}],"predecessor-version":[{"id":10142,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10137\/revisions\/10142"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10138"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}